Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration

Figure 6

Changes in proportion of patients have IRF on SD-OCT. The proportion of patients with IRF did not change statistically significantly during the treatment of IVC. After switching to IVR or IVB, this proportion decreased significantly from 96.9% to 81.3% at T3 and 71.9% at T4. IRF, intraretinal fluid; IVC, intravitreal injections of conbercept; IVB, intravitreal injection of bevacizumab; IVR, intravitreal injection of ranibizumab; T0, baseline visit; T1, 1 month after the first ICV; T2, 1 month after 3 monthly IVC; T3, 1 month after the first IVR or IVB; T4, 1 month after the last IVR or IVB.).